Why Tvardi Therapeutics, Inc.’s (TVRD) Stock Is Down 6.30%
As of Wednesday, October 22, Tvardi Therapeutics, Inc.’s TVRD share price has dipped by 6.30%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Commentary & Analysis
Why Tvardi Therapeutics, Inc.’s (TVRD) Stock Is Down 8.05%
As of Monday, October 20, Tvardi Therapeutics, Inc.’s TVRD share price has dipped by 8.05%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Tvardi Therapeutics, Inc.’s (TVRD) Stock Is Up 6.48%
As of Thursday, October 16, Tvardi Therapeutics, Inc.’s TVRD share price has surged by 6.48%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Tvardi Therapeutics, Inc.’s (TVRD) Stock Is Down 5.51%
As of Wednesday, October 15, Tvardi Therapeutics, Inc.’s TVRD share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tvardi Therapeutics, Inc.’s (TVRD) Stock Is Down 83.79%
As of Monday, October 13, Tvardi Therapeutics, Inc.’s TVRD share price has dipped by 83.79%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | TVRD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $17.4 | $646.7 | 9% |
|
| Shares Out (Mil) | 9.4 | 44.2 | 19% |
|
| Institutional Ownership | 53.7% | 85.5% | 36% |
|
| Float (Mil) | 5.7 | 47.3 | 13% |
|
| Beta | na | 0.69 | na |
|
| Avg Daily Volume (000s) | 197 | 391 | 44% |
|
| Price Change (52-week) |
(93.1%) | 69.0% | 3% |
|
| Growth | TVRD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.586) | ($2.373) | ($2.266) | |
| Month Ago EPS | ($0.526) | ($2.343) | ($2.729) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.483) | ($2.198) | ($2.282) | |
| Year/Year Chg | (15.1%) | (27.2%) | (12.3%) | |
| Financials | TVRD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($26) | ($11) | 22% |
|
| EPS (TTM) | ($2.774) | ($0.700) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | ($6) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $2 | $463 | 4% |
|
| Valuation | TVRD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.09 | 2.81 | 51% |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TVRD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.1% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (85.1%) | (23.4%) | 7% |
|
| ROE | (126.2%) | (20.6%) | 7% |
|
| Liabilities to Assets | 52.1% | 32.0% | 45% |
|
| F-Score | 1 | 3 | 1% |
|
Tvardi Therapeutics, Inc. did not pass any screens on 8/21/2026.
